Over 5% Shareholder Equity Fully Distributed: What Happened to the Rare Disease Drug Developer?

On January 28, Tactic Pharma LLC, an early investor in rare-disease therapy developer Monopar Therapeutics (MNPR), distributed all its remaining common shares to its members, reducing its stake to zero. As a result, Tactic Pharma and related reporting persons Chandler Robinson and Michael J. Brown have been removed from the list of shareholders holding more than 5% of Monopar’s outstanding stock. This filing serves as the final amended report notifying the end of their equity holdings; it does not include any plans for shareholder activism, such as board participation or strategic shifts.

Monopar has recently drawn investor interest after BTIG reiterated a “Buy” rating and a $104 price target as the company prepares to submit a New Drug Application (NDA) for its Wilson’s disease candidate ALXN1840 to the U.S. Food and Drug Administration (FDA) in the first half of 2026.

Monopar is a clinical-stage biotech that in-licensed ALXN1840 from AstraZeneca’s rare disease division, Alexion. The company is restructuring the Phase III asset to pursue U.S. approval and is expanding its pipeline with radiopharmaceutical candidates, including the MNPR-101 series.